The primary endpoint of this study was the tolerance/hypoallergenicity of the new AAF in infants with CMPAand intolerance to eHFs at 1 month. It was defined as theabsence, for these infants, of allergy symptoms that led tostudy termination during the first month. The secondaryendpoints were (i) resolution of the dominant CMPAsymptom, (ii) resolution of other CMPA symptoms, (iii)resolution of general symptoms potentially associated withCMPA and related to daily family life, and (iv) anthropometric variables in accordance with WHO growth curves.